TALZENNA DIN 02492040
Status: Approved
Holder: PFIZER CANADA ULC
Health Canada record
| Active ingredient(s) | TALAZOPARIB (TALAZOPARIB TOSYLATE) 1 MG |
|---|
| Dosage form | Capsule |
|---|
| Route | Oral |
|---|
| Schedule | PRESCRIPTION |
|---|
| Class | Human |
|---|
| ATC | L01XK04 TALAZOPARIB |
|---|
| Original market date | |
|---|
| Current status date | 06-Sep-2019 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Pfizer Canada ULC — licence 100255, currently licensed, last inspection rating C (2023-08-07).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing TALAZOPARIB (TALAZOPARIB TOSYLATE)
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02492032 | TALZENNA | PFIZER CANADA ULC | Capsule | TALAZOPARIB (TALAZOPARIB TOSYLATE) 0.25 MG | Marketed |
| 02555050 | TALZENNA | PFIZER CANADA ULC | Capsule | TALAZOPARIB (TALAZOPARIB TOSYLATE) 0.1 MG | Marketed |
| 02555069 | TALZENNA | PFIZER CANADA ULC | Capsule | TALAZOPARIB (TALAZOPARIB TOSYLATE) 0.35 MG | Approved |
| 02555077 | TALZENNA | PFIZER CANADA ULC | Capsule | TALAZOPARIB (TALAZOPARIB TOSYLATE) 0.5 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 22615 | 2019-09-06 | New Drug Submission (NDS) | |
Request a quote for TALZENNA
How to read a Canadian DIN record